{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:10:40Z","timestamp":1790831440736,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T00:00:00Z","timestamp":1540425600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000015","name":"Canadian Cancer Society Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Vancouver General Hospital"},{"name":"University of British Columbia Hospital Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4970-9","type":"journal-article","created":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T12:35:36Z","timestamp":1540470936000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Long-term mortality among women with epithelial ovarian cancer: a population-based study in British Columbia, Canada"],"prefix":"10.1186","volume":"18","author":[{"given":"Nimisha","family":"Arora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Talhouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica N.","family":"McAlpine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9594-0545","authenticated-orcid":false,"given":"Gillian E.","family":"Hanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,25]]},"reference":[{"key":"4970_CR1","unstructured":"Canadian Cancer Society's Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2014 - Special Topic: Skin Cancers. Canadian Cancer Society; 2014. \n                    http:\/\/www.cancer.ca\n                    \n                  \/. Accessed 20 May 2017."},{"key":"4970_CR2","unstructured":"Canadian Cancer Society's Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2016 - Special topic: HPV-associated cancers; 2016. \n                    http:\/\/www.cancer.ca\n                    \n                  \/. Accessed 20 May 2017."},{"key":"4970_CR3","unstructured":"Nuttall R. Canadian cancer statistics 2017. Canadian Cancer Society; 2017. \n                    http:\/\/www.cancer.ca\/\n                    \n                  . Accessed 20 July 2017."},{"issue":"4","key":"4970_CR4","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1136\/ebmed-2016-110385","volume":"21","author":"Juan G\u00e9rvas","year":"2016","unstructured":"G\u00e9rvas J. Ovarian cancer screening: could you recommend it? No. EBM 2016; doi: \n                    https:\/\/doi.org\/10.1136\/ebmed-2016-110385\n                    \n                  .","journal-title":"Evidence Based Medicine"},{"issue":"2","key":"4970_CR5","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ygyno.2015.06.005","volume":"138","author":"Helen E. Dinkelspiel","year":"2015","unstructured":"Dinkelspiel HE, Champer M, Hou J, et al. Long-term mortality among women with epithelial ovarian cancer. Gynecol Oncol. 2015. \n                    https:\/\/doi.org\/10.1016\/j.ygyno.2015.06.005\n                    \n                  .","journal-title":"Gynecologic Oncology"},{"issue":"30","key":"4970_CR6","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1200\/JCO.2010.32.6462","volume":"29","author":"Edoardo Colzani","year":"2011","unstructured":"Colzani E, Liljegren A, Johansson ALV, et al. Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis, age, and tumor characteristics. JOC 2011; doi: \n                    https:\/\/doi.org\/10.1200\/JCO.2010.32.6462\n                    \n                  .","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"4970_CR7","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/bju.13059","volume":"117","author":"Mieke Van Hemelrijck","year":"2015","unstructured":"Van Hemelrijck M, Folkvaljon Y, Adolfsson J, et al. Causes of death in men with localized prostate cancer: a nationwide, population-based study. BJU Int. 2016. \n                    https:\/\/doi.org\/10.1111\/bju.13059\n                    \n                  .","journal-title":"BJU International"},{"key":"4970_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.oraloncology.2016.12.006","volume":"65","author":"Sean T. Massa","year":"2017","unstructured":"Massa ST, Osazuwa-Peters N, Christopher KM, et al. Competing causes of death in the head and neck cancer population. Oral Oncol. 2017. \n                    https:\/\/doi.org\/10.1016\/j.oraloncology.2016.12.006\n                    \n                  .","journal-title":"Oral Oncology"},{"issue":"5","key":"4970_CR9","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1093\/annonc\/mdv061","volume":"26","author":"M. L. G. Janssen-Heijnen","year":"2015","unstructured":"Janssen-Heijnen MLG, van Erning FN, De Ruysscher DK, Coebergh JWW, Groen HJM. Variation in causes of death in patients with non-small cell lung cancer according to stage and time since diagnosis. Ann Oncol. 2015. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdv061\n                    \n                  .","journal-title":"Annals of Oncology"},{"key":"4970_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.bpobgyn.2016.08.006","volume":"41","author":"Penelope M. Webb","year":"2017","unstructured":"Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017. \n                    https:\/\/doi.org\/10.1016\/j.bpobgyn.2016.08.006\n                    \n                  .","journal-title":"Best Practice & Research Clinical Obstetrics & Gynaecology"},{"issue":"8","key":"4970_CR11","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/bjc.2016.273","volume":"115","author":"Stefan Kommoss","year":"2016","unstructured":"Kommoss S, Gilks CB, du Bois A, Kommoss F. Ovarian carcinoma diagnosis: the clinical impact of 15 years of change. Br J Cancer. 2016. \n                    https:\/\/doi.org\/10.1038\/bjc.2016.273\n                    \n                  .","journal-title":"British Journal of Cancer"},{"issue":"2","key":"4970_CR12","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.ygyno.2016.10.019","volume":"144","author":"Melissa Matz","year":"2017","unstructured":"Matz M, Coleman MP, Sant M, et al. The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2). Gynecol Oncol. 2017. \n                    https:\/\/doi.org\/10.1016\/j.ygyno.2016.10.019\n                    \n                  .","journal-title":"Gynecologic Oncology"},{"issue":"2","key":"4970_CR13","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ygyno.2016.11.019","volume":"144","author":"Melissa Matz","year":"2017","unstructured":"Matz M, Coleman MP, Carreira H, Salmer\u00f3n D, Chirlaque MD, Allemani C. Worldwide comparison of ovarian cancer survival: histological group and stage at diagnosis (CONCORD-2). Gynecol Oncol. 2017. \n                    https:\/\/doi.org\/10.1016\/j.ygyno.2016.11.019\n                    \n                  .","journal-title":"Gynecologic Oncology"},{"issue":"8","key":"4970_CR14","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.humpath.2008.01.003","volume":"39","author":"C. Blake Gilks","year":"2008","unstructured":"Gilks CB, Ionescu DN, Kalloger SE, et al. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol. 2008. \n                    https:\/\/doi.org\/10.1016\/j.humpath.2008.01.003\n                    \n                  .","journal-title":"Human Pathology"},{"issue":"12","key":"4970_CR15","doi-asserted-by":"publisher","first-page":"e232","DOI":"10.1371\/journal.pmed.0050232","volume":"5","author":"Martin K\u00f6bel","year":"2008","unstructured":"K\u00f6bel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 2008. \n                    https:\/\/doi.org\/10.1371\/journal.pmed.0050232\n                    \n                  .","journal-title":"PLoS Medicine"},{"key":"4970_CR16","unstructured":"BC cancer agency registry data (2011). Population data BC. BC cancer agency. 2011 \n                    http:\/\/www.popdata.bc.ca\/data\n                    \n                  . Accessed 20 May 2017."},{"key":"4970_CR17","unstructured":"BC Vital Statistics Agency (2011). Vital statistics deaths. Population data BC BC vital statistics agency (2011). \n                    http:\/\/www.popdata.bc.ca\/data\n                    \n                  . Accessed 20 May 2017."},{"key":"4970_CR18","unstructured":"British Columbia Ministry of Heath (2011): Consolidation file (MSP registration and premium billing). Population data BC MOH (2011). \n                    http:\/\/www.popdata.bc.ca\/data\n                    \n                  . Accessed 20 May 2017."},{"key":"4970_CR19","volume-title":"Equity in the use and financing of medicines in British Columbia before and after the move to income-based pharma care","author":"GE Hanley","year":"2011","unstructured":"Hanley GE. Equity in the use and financing of medicines in British Columbia before and after the move to income-based pharma care. 2011. \n                    https:\/\/open.library.ubc.ca\n                    \n                  . Accessed 10 December 2017."},{"key":"4970_CR20","unstructured":"About popdata. \n                    https:\/\/www.popdata.bc.ca\n                    \n                  \/. Accessed 16 April 2017."},{"key":"4970_CR21","unstructured":"RStudio team (2016). RStudio: Integrated development for R. RStudio, inc., boston, MA URL \n                    http:\/\/www.rstudio.com\n                    \n                  \/. Accessed 17 May 2017."},{"issue":"12","key":"4970_CR22","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1001\/jamasurg.2014.1081","volume":"149","author":"Alexandra Gangi","year":"2014","unstructured":"Gangi A, Cass I, Paik D, et al. Breast cancer following ovarian cancer inBRCAMutation carriers. JAMA Surg. 2014. \n                    https:\/\/doi.org\/10.1001\/jamasurg.2014.1081\n                    \n                  .","journal-title":"JAMA Surgery"},{"issue":"2","key":"4970_CR23","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ygyno.2017.02.032","volume":"145","author":"Jacob McGee","year":"2017","unstructured":"McGee J, Giannakeas V, Karlan B, et al. Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: is preventive mastectomy warranted? Gynecol Oncol. 2017. \n                    https:\/\/doi.org\/10.1016\/j.ygyno.2017.02.032\n                    \n                  .","journal-title":"Gynecologic Oncology"},{"issue":"3","key":"4970_CR24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/14737140.2018.1424547","volume":"18","author":"Joanne Kotsopoulos","year":"2018","unstructured":"Kotsopoulos J, Narod SA. Prophylactic mastectomy for BRCA mutation carriers after ovarian cancer treatment: is it beneficial? Expert Rev Anticancer Ther. 2018. \n                    https:\/\/doi.org\/10.1080\/14737140.2018.1424547\n                    \n                  .","journal-title":"Expert Review of Anticancer Therapy"},{"issue":"7","key":"4970_CR25","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/his.12349","volume":"64","author":"Martin K\u00f6bel","year":"2014","unstructured":"K\u00f6bel M, Bak J, Bertelsen BI, et al. Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry. Histopathology. 2014. \n                    https:\/\/doi.org\/10.1111\/his.12349\n                    \n                  .","journal-title":"Histopathology"},{"issue":"1","key":"4970_CR26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ygyno.2014.07.100","volume":"135","author":"Koah R. Vierkoetter","year":"2014","unstructured":"Vierkoetter KR, Ayabe AR, VanDrunen M, Ahn HJ, Shimizu DM, Terada KY. Lynch syndrome in patients with clear cell and endometrioid cancers of the ovary. Gynecol Oncol. 2014. \n                    https:\/\/doi.org\/10.1016\/j.ygyno.2014.07.100\n                    \n                  .","journal-title":"Gynecologic Oncology"},{"issue":"2, Part 1","key":"4970_CR27","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/AOG.0b013e31825f3576","volume":"120","author":"Kasmintan A. Schrader","year":"2012","unstructured":"Schrader KA, Hurlburt J, Kalloger SE, et al. Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy. Obstet Gynecol. \n                    https:\/\/doi.org\/10.1097\/AOG.0b013e31825f3576\n                    \n                  .","journal-title":"Obstetrics & Gynecology"},{"key":"4970_CR28","doi-asserted-by":"publisher","unstructured":"Hanley GE, McAlpine JN, Miller D, et al. A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention. BMC Cancer. 2018. \n                    https:\/\/doi.org\/10.1186\/s12885-018-4153-8\n                    \n                  .","DOI":"10.1186\/s12885-018-4153-8"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4970-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-4970-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4970-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T13:53:54Z","timestamp":1572011634000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4970-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,25]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4970"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4970-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,25]]},"assertion":[{"value":"30 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The University of British Columbia\u2019s behavioural research ethics board has approved the study. As the data linkage maintained patient anonymity (all identifiers were removed before being provided to the researchers) and the population-based administrative datasets in BC operate based on passive consent (i.e. patients may withdraw their consent and their data will be removed from the administrative datasets), direct patient consent was not required.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"1039"}}